ROCKVILLE, MD — (Marketwire) — 01/25/12 — MarketResearch.com has announced the addition of the new report “Antipsychotics Market to 2017 – Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules,” to their collection of Pharmaceuticals market reports. For more information, visit
Antipsychotic drugs remain the standard care for the treatment of mental disorders such as schizophrenia and bipolar disorder. The global antipsychotic market for such treatments is made up of 70% schizophrenia therapeutics and 30% bipolar disorder therapeutics.
The global antipsychotics market has shown a rising trend from 2002, growing at a Compound Annual Growth Rate (CAGR) of 4.8% to reach $14 billion in 2010. Newer agents (atypical antipsychotics) such as AstraZeneca-s Seroquel (quetiapine fumarate), Eli Lilly-s Zyprexa (olanzapine), Bristol-Myers Squibb-s Abilify (aripiprazole), Johnson & Johnson-s (J&J) Risperdal (risperidone) and Pfizer-s Geodon (ziprasidone HCl) were rapidly adopted during this period due to their better efficacy when compared with typical antipsychotics and these drugs achieved blockbuster status.
However, the patent expiries of the leading antipsychotics such as Zyprexa, Abilify, Geodon, and Seroquel in the forecast period, followed by the immediate entry of generic versions are expected to increase price competition in the global antipsychotics market and so may limit the commercial opportunities to pipeline molecules. As a result the global antipsychotics market is expected to decline at a CAGR of 0.4% from $14 billion in 2010 to $13.8 billion in 2017.
The US was the major contributor to the antipsychotics market in 2010 with a share of 58%.It was followed by the top five countries of Europe and Japan which accounted for 30% and 12% respectively. The high prevalence rates of schizophrenia and bipolar disorders among the growing geriatric population, comparatively better disease awareness and treatment seeking rate are some of primary reasons that made the US the leading contributor of the antipsychotics market in 2010.
However, the trend towards use of generics, reimbursement issues, patent expirations, safety issues and a reduction in inventive product launches have worsened the economic slowdown of this sector in the US. The generic drug segment is expected to see rapid growth due to the patent expiry of major antipsychotics which may result in limited commercial opportunities for pipeline molecules.
For more information, visit
MarketResearch.com is the leading provider of global market intelligence products and services. With over 300,000 research reports from more than 700 top consulting and advisory firms, MarketResearch.com offers instant online access to the world-s most extensive database of expert insights on global industries, companies, products, and trends. For more information, call Veronica Franco at 240-747-3016 or visit .
Contact:
Veronica Franco
MarketResearch.com
240.747.3016
You must be logged in to post a comment Login